ANI Pharmaceuticals Inc [ANIP] stock is trading at $61.91, up 5.43%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ANIP shares have gain 7.13% over the last week, with a monthly amount drifted -12.42%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ANI Pharmaceuticals Inc [NASDAQ: ANIP] stock has seen the most recent analyst activity on March 14, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $80. Previously, JP Morgan started tracking the stock with Overweight rating on March 12, 2025, and set its price target to $85. On December 11, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $80 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $68 on October 11, 2024. CapitalOne initiated its recommendation with a Overweight and recommended $80 as its price target on March 15, 2024. H.C. Wainwright reiterated a Buy rating for this stock on August 22, 2023, and upped its price target to $73. In a note dated March 01, 2023, Guggenheim initiated an Buy rating and provided a target price of $55 on this stock.
ANI Pharmaceuticals Inc [ANIP] stock has fluctuated between $52.50 and $77.00 over the past year. Currently, Wall Street analysts expect the stock to reach $86 within the next 12 months. ANI Pharmaceuticals Inc [NASDAQ: ANIP] shares were valued at $61.91 at the most recent close of the market. An investor can expect a potential return of 38.91% based on the average ANIP price forecast.
Analyzing the ANIP fundamentals
ANI Pharmaceuticals Inc [NASDAQ:ANIP] reported sales of 674.07M for the trailing twelve months, which represents a growth of 43.43%. Gross Profit Margin for this corporation currently stands at 0.57% with Operating Profit Margin at 0.01%, Pretax Profit Margin comes in at -0.04%, and Net Profit Margin reading is -0.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.05 and Total Capital is 0.01. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.76.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, ANI Pharmaceuticals Inc’s Current Ratio is 2.66. Also, the Quick Ratio is 1.98, while the Cash Ratio stands at 0.74. Considering the valuation of this stock, the price to sales ratio is 1.99, the price to book ratio is 3.21.
Transactions by insiders
Recent insider trading involved Gutwerg Ori, SVP, GENERICS, that happened on May 15 ’25 when 881.0 shares were sold. HEAD OF RARE DISEASE, Mutz Christopher completed a deal on May 14 ’25 to sell 4000.0 shares. Meanwhile, SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold 400.0 shares on May 13 ’25.
